Quick Answer
Aligos Therapeutics, Inc. reported Net Income Loss of -$24.19 million for the year ending 2025.
- Aligos Therapeutics, Inc. showed an increase of +81.6% in Net Income Loss from 2024 to 2025.
- This data is from Aligos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$14.05 million | Q1 2020: -$20.03 million | Q2 2020: -$20.80 million | Q3 2020: -$33.30 million | Q1 2021: -$27.67 million | Q2 2021: -$29.82 million | Q3 2021: -$33.12 million | Q1 2022: -$35.62 million | Q2 2022: -$19.92 million | Q3 2022: -$18.62 million | Q1 2023: -$22.96 million | Q2 2023: -$18.79 million | Q3 2023: -$18.04 million | Q1 2024: -$34.86 million | Q2 2024: $5.06 million | Q3 2024: -$19.26 million | Q1 2025: $43.09 million | Q2 2025: -$15.86 million | Q3 2025: -$31.54 million.
- Over the full 7 years of available data (2019 to 2025), Aligos Therapeutics, Inc.'s Net Income Loss has grown by 53.7%.
- Historical annual values: Fiscal year 2025: -$24.19 million | Fiscal year 2024: -$131.21 million | Fiscal year 2023: -$87.68 million | Fiscal year 2022: -$96.05 million | Fiscal year 2021: -$128.33 million | Fiscal year 2020: -$108.54 million | Fiscal year 2019: -$52.26 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: